Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Titel:
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study
Auteur:
Costa Clemens, Sue Ann Jepson, Brett Bhorat, Qasim E Ahmad, Abdullahi Akhund, Tauseefullah Aley, Parvinder K Bansal, Himanshu Bibi, Sagida Kelly, Elizabeth J Khan, Mark Lambe, Teresa Lombaard, Johan J Matthews, Sam Pipolo Milan, Eveline Olsson, Urban Ramasamy, Maheshi N Moura de Oliveira Paiva, Maria Sanali Seegobin, Seth Shoemaker, Kathryn Szylak, Ameena Villafana, Tonya Pollard, Andrew J Green, Justin A